Prognostic significance of hepatic encephalopathy in patients with cirrhosis treated with current standards of care.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Baishideng Publishing Group Country of Publication: United States NLM ID: 100883448 Publication Model: Print Cited Medium: Internet ISSN: 2219-2840 (Electronic) Linking ISSN: 10079327 NLM ISO Abbreviation: World J Gastroenterol Subsets: MEDLINE
    • Publication Information:
      Publication: 2014- : Pleasanton, CA : Baishideng Publishing Group
      Original Publication: Beijing : WJG Press, c1998-
    • Subject Terms:
      Hepatic Encephalopathy/*mortality ; Liver Cirrhosis/*therapy ; Liver Transplantation/*standards; Aged ; Clinical Decision-Making ; Female ; Follow-Up Studies ; Hepatic Encephalopathy/drug therapy ; Hepatic Encephalopathy/etiology ; Humans ; Kaplan-Meier Estimate ; Lactulose/therapeutic use ; Liver Cirrhosis/complications ; Liver Cirrhosis/diagnosis ; Liver Cirrhosis/mortality ; Male ; Middle Aged ; Patient Selection ; Prognosis ; Retrospective Studies ; Rifaximin/therapeutic use ; Severity of Illness Index ; Standard of Care ; Treatment Outcome
    • Abstract:
      Background: Hepatic encephalopathy (HE) is a reversible neuropsychiatric complication of liver cirrhosis and occurs in up to 50% of cirrhotic patients. Studies examining the prognostic significance of HE are limited despite the high prevalence in cirrhosis.
      Aim: To define the clinical outcomes of patients after an episode of HE treated with current standards-of-care.
      Methods: All patients hospitalised with HE requiring Rifaximin to 3 tertiary centres over 46-mo (2012-2016) were identified via pharmacy dispensing records. Patients with hepatocellular carcinoma and those prescribed Rifaximin prior to admission were excluded. Medical records were reviewed to determine baseline characteristics and survival. The Kaplan-Meier method was used to calculate survival probability. Univariate survival analysis was performed with variables reaching statistical significance included in a multivariate analysis. The primary outcome was 12-mo mortality following commencement of Rifaximin.
      Results: 188 patients were included. Median age was 57 years (IQR 50-65), 71% were male and median model for end stage liver disease and Child Pugh scores were 25 (IQR 18-31) and 11 (IQR 9-12) respectively. The most common causes of cirrhosis were alcohol (62%), hepatitis C (31%) and non-alcoholic fatty liver disease (20%). A precipitating cause for HE was found in 92% patients with infection (43%), GI bleeding (16%), medication non-compliance (15%) and electrolyte imbalance (14%) the most common. During a mean follow up period of 12 ± 13 mo 107 (57%) patients died and 32 (17%) received orthotopic liver transplantation. The most common causes of death were decompensated chronic liver disease (57%) and sepsis (19%). The probability of survival was 44% and 35% at 12- and 24-mo respectively. At multivariate analysis a model for end stage liver disease > 15 and international normalised ratio reached statistical significance in predicting mortality.
      Conclusion: Despite advances made in the management of HE patients continue to have poor survival. Thus, in all patients presenting with HE the appropriateness of orthotopic liver transplantation should be considered.
      Competing Interests: Conflict-of-interest statement: We have no financial relationships to disclose.
      (©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.)
    • References:
      Am J Transplant. 2005 Feb;5(2):307-13. (PMID: 15643990)
      Am J Gastroenterol. 2013 Sep;108(9):1458-63. (PMID: 23877348)
      Liver Int. 2012 Oct;32(9):1407-14. (PMID: 22679906)
      Am J Gastroenterol. 2001 Sep;96(9):2718-23. (PMID: 11569701)
      JAMA Intern Med. 2014 Nov;174(11):1727-33. (PMID: 25243839)
      J Hepatol. 1999 May;30(5):890-5. (PMID: 10365817)
      Hepatology. 1992 Jul;16(1):138-44. (PMID: 1618465)
      Hepatology. 2014 Aug;60(2):715-35. (PMID: 25042402)
      Gastroenterology. 2014 Feb;146(2):412-19.e3. (PMID: 24148622)
      J Hepatol. 2006 Jan;44(1):217-31. (PMID: 16298014)
      Aliment Pharmacol Ther. 2017 Nov;46(9):845-855. (PMID: 28836723)
      Scand J Gastroenterol. 1989 Apr;24(3):269-76. (PMID: 2734585)
      Liver Transpl. 2007 Oct;13(10):1366-71. (PMID: 17520742)
      Hepatology. 1987 Jan-Feb;7(1):122-8. (PMID: 3804191)
      Aliment Pharmacol Ther. 2010 Mar;31(5):537-47. (PMID: 20002027)
      Hepatology. 2002 Mar;35(3):716-21. (PMID: 11870389)
      Gastroenterol Rep (Oxf). 2017 May;5(2):138-147. (PMID: 28533911)
      Cochrane Database Syst Rev. 2019 Jan 05;1:CD011451. (PMID: 30610762)
      Clin Ther. 2016 May;38(5):1081-1089.e4. (PMID: 27136714)
      J Gastroenterol Hepatol. 2017 Jun;32(6):1234-1239. (PMID: 27885712)
      Gut. 2003 Jan;52(1):134-9. (PMID: 12477775)
      Dig Endosc. 2019 Nov 4;:. (PMID: 31863515)
      N Engl J Med. 2010 Mar 25;362(12):1071-81. (PMID: 20335583)
      J Clin Exp Hepatol. 2015 Mar;5(Suppl 1):S37-41. (PMID: 26041955)
      J Hepatol. 2003 Apr;38(4):441-6. (PMID: 12663235)
      Clin Gastroenterol Hepatol. 2005 Feb;3(2):184-91. (PMID: 15704053)
      Clin Gastroenterol Hepatol. 2009 Jun;7(6):689-95. (PMID: 19281860)
      J Hepatol. 2014 Sep;61(3):642-59. (PMID: 25015420)
    • Contributed Indexing:
      Keywords: Cirrhosis; Hepatic encephalopathy; Lactulose; Portal hypertension; Prognosis; Rifaximin
    • Accession Number:
      4618-18-2 (Lactulose)
      L36O5T016N (Rifaximin)
    • Publication Date:
      Date Created: 20200602 Date Completed: 20210208 Latest Revision: 20210208
    • Publication Date:
      20231215
    • Accession Number:
      PMC7235207
    • Accession Number:
      10.3748/wjg.v26.i18.2221
    • Accession Number:
      32476788